ZimVie price target raised to $11 from $7 at Barclays

Barclays analyst Matt Miksic raised the firm’s price target on ZimVie to $11 from $7 but keeps an Underweight rating on the shares after its Q2 results. The analyst is more positive given the slower declines in ZimVie’s Spine business, though the firm remains concerned about the contracting growth combined with the company’s relatively high debt levels.